PeptiDream (TYO:4587) reached an undisclosed development milestone in its peptide cytotoxic conjugate program in collaboration with U.S. pharmaceutical company MSD, triggering a milestone payment, according to a Wednesday filing with the Tokyo Stock Exchange.
The Japanese biopharmaceutical firm did not disclose the specific milestone reached or the payment amount.
PeptiDream said the payment was already factored into its 2026 earnings forecast, which remains unchanged.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.